Piringer Gudrun, Decker Jörn, Trommet Vera, Kühr Thomas, Heibl Sonja, Dörfler Konrad, Thaler Josef
Department of Internal Medicine IV, Wels-Grieskirchen Medical Hospital, Wels, Austria.
Department of Hematology and Oncology, Kepler University Hospital, Linz, Austria.
Front Oncol. 2023 May 5;13:1166545. doi: 10.3389/fonc.2023.1166545. eCollection 2023.
Metastatic BRAF mutated colorectal cancer is associated with poor overall survival and modest effectiveness to standard therapies. Furthermore, survival is influenced by the microsatellite status. Patients with microsatellite-stable and BRAF mutated colorectal cancer have the worst prognosis under the wide range of genetic subgroups in colorectal cancer. Herein, we present a patient case of an impressive therapeutic efficacy of dabrafenib, trametinib, and cetuximab as later-line therapy in a 52-year-old woman with advanced BRAF mutated, microsatellite-stable colon cancer. This patient achieved a complete response after 1 year of triple therapy. Due to skin toxicity grade 3 and recurrent urinary tract infections due to mucosal toxicity, a therapy de-escalation to dabrafenib and trametinib was performed, and the double therapy was administered for further 41 months with ongoing complete response. For 1 year, the patient was off therapy and is still in complete remission.
转移性BRAF突变型结直肠癌与总体生存率低以及对标准疗法的疗效一般有关。此外，生存率受微卫星状态影响。在结直肠癌的广泛基因亚组中，微卫星稳定且BRAF突变的结直肠癌患者预后最差。在此，我们报告一例52岁患有晚期BRAF突变、微卫星稳定型结肠癌女性患者的病例，其接受达拉非尼、曲美替尼和西妥昔单抗作为后线治疗取得了令人瞩目的治疗效果。该患者在三联疗法治疗1年后达到完全缓解。由于3级皮肤毒性以及黏膜毒性导致的复发性尿路感染，治疗方案降级为达拉非尼和曲美替尼，双药治疗持续41个月，患者仍保持完全缓解。患者停药1年，目前仍处于完全缓解状态。
